Wanted: A Non-Profit to Run as Many Low-Cost Trials of Promising Treatments for Aging as Possible

A major gap exists in the present spectrum of efforts to develop the means to treat aging, rejuvenate the old, and turn back age-related conditions. An the one hand, a small number of promising potential therapies to treat the mechanisms of aging can at present be applied by physicians off-label, or otherwise without the need for a great deal of interaction with the FDA. On the other hand, there are a good hundred or more clinical indications, specific age-related conditions recognized by regulatory authorities, that might be improved by these therapies. Several hundred small, informal trials could be run, starting now, given approaches that presently exist, in order to determine whether or not these forms of therapy are in fact effective. Let us only consider the senolytic combination of dasatinib and quercetin, for example, a low-cost treatment that can be given off-label and that has been demonstrated to clear senescent cells in human patients. Clearance of senescent cells in mice produces profound and rapid rejuvenation. Senolytics as a class of therapy are at present in human trials for only a few indications: osteoarthritis, idiopathic pulmonary fibrosis, COVID-19, chronic kidney disease, and recently Alzheimer's disease. The whole senolytic industry, and associated academic trial groups, after nearly ten years of development, has done no more than initiate a few formal human trials, at great expense, and which are very slow to answer the question of whether this...
Source: Fight Aging! - Category: Research Authors: Tags: Activism, Advocacy and Education Source Type: blogs